Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. AAPL
6. RTB
7. ONON
8. AZN
9. SPCX
10. TRMD

Go back to Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
(NASDAQ: ORGO) Delayed: 1.42 +0.06 (4.41%)
Previous Close $1.36    52 Week High $ 
Open $1.36    52 Week Low $ 
Day High $1.42    P/E N/A 
Day Low $1.34    EPS $ 
Volume 1,003,440